[A21-42] Tafamidis (transthyretin amyloidosis with cardiomyopathy) - Addendum to Commission A20-102
Last updated 20.05.2021
Project no.:
A21-42
Commission:
Commission awarded on 08.04.2021 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Heart and circulation
Wild-type or hereditary transthyretin amyloid cardiomyopathy (ATTR-CM) in adult patients
Patients with NYHA class I + II cardiac failure: hint of major added benefit.
Patients with NYHA class III cardiac failure: hint of considerable added benefit.
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A20-102 | Tafamidis (transthyretin amyloidosis with cardiomyopathy) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2021.05.20 A G-BA decision was published.